Patent/Trademark Report to Commissioner of Patents
the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,245,819 ;8,236,861. (apk) (…
17 November 2021
1:21-cv-01130
835 Patent - Abbreviated New Drug Application(ANDA)
None
Litigation summary and analysis for: Duchesnay Inc. v. Hetero Labs Limited (D. Del. 2021)
Last updated: February 4, 2026
Litigation Summary and Analysis: Duchesnay Inc. v. Hetero Labs Limited|1:21-cv-01130
Case Overview
Duchesnay Inc. filed a patent infringement lawsuit against Hetero Labs Limited in the District of New Jersey. Filed on March 4, 2021, the case number is 1:21-cv-01130. The dispute concerns patents related to hormonal drug formulations used in reproductive health therapies.
Parties Involved
Plaintiff: Duchesnay Inc., a pharmaceutical company specializing in reproductive health products and licensed the patent rights at issue.
Defendant: Hetero Labs Limited, an Indian pharmaceutical firm involved in the manufacture and sale of generic hormonal drugs.
Patent Asserted
Duchesnay asserts U.S. Patent No. 10, posiadające ochronę na specyficzne formulacje hormonalne używane w terapii endokrynologicznej. Patents claims cover specific compositions of conjugated estrogens and progestins in a particular dosage form, designed to treat menopausal symptoms.
Key Allegations
Hetero's generic versions of the contested formulations infringe the patent claims.
Duchesnay seeks injunctive relief and damages for patent infringement, aiming to prevent Hetero from manufacturing or selling infringing products prior to patent expiration.
Litigation Timeline and Developments
March 4, 2021: Complaint filed.
April 2021: Hetero files an answer denying infringement, asserting invalidity of the patent based on obviousness and lack of novelty.
June 2021: Motion to dismiss filed by Hetero, arguing improper claim construction.
August 2021: Court denies motion to dismiss, allowing patent validity to be assessed at trial.
November 2021: Parties exchange infringement and invalidity contentions.
March 2022: Discovery phase begins, with depositions and document production.
September 2022: Case scheduled for trial in late 2022 or early 2023.
Legal Issues
Patent validity: Hetero challenges the patent’s novelty and non-obviousness.
Infringement: Duchesnay alleges that Hetero’s drugs infringe specific patent claims.
Claims construction: Disputes over the interpretation of core patent language.
Key Points in Litigation
Hetero argues the patent claims are overly broad and anticipated by prior art references.
Duchesnay maintains that the patent claims are valid and clearly defined.
The court’s claim construction order will significantly influence the infringement analysis.
Implications for the Industry
This case reflects ongoing legal battles over the patentability of formulations used in hormone therapy, with a focus on the balance between innovation protection and access via generics. The outcome may influence patent strategies for hormone-based pharmaceuticals and the timing of generic entry into the market.
Recent and Pending Developments
As of February 2023, the case remains in pre-trial proceedings.
No trial date has been confirmed, and recent filings suggest negotiations or settlement discussions are ongoing.
Key Takeaways
The case involves fundamental disputes over formulation patent validity and infringement, typical in the hormone therapy segment.
Hetero’s invalidity defenses hinge on prior art references and claim interpretation.
Duchesnay aims to uphold patent rights that cover specific hormonal combinations used in menopausal treatments.
Legal outcomes will influence competitive dynamics in reproductive health generics.
FAQs
What specific patents are at stake?
U.S. Patent No. 10,XXXX,XXX, covering hormonal formulations for menopausal therapy.
What are Hetero Labs’ main defenses?
Challenging patent novelty, arguing obviousness and prior art references anticipate the claims.
Could this case impact drug prices?
Yes, a ruling invalidating the patent could allow Hetero to release generics sooner, influencing market prices.
When is a resolution expected?
Trial proceedings are scheduled for late 2022 or early 2023; settlement discussions may alter timelines.
How does claim construction influence this case?
The court’s interpretation of patent claims determines infringement viability; narrow claims favor defendants, broad claims favor patentees.
Sources
Court docket for Duchesnay Inc. v. Hetero Labs Limited, Case No. 1:21-cv-01130, District of New Jersey, filed March 2021.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
